Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study

This publication has 27 references indexed in Scilit:

• Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: Do the benefits add up?
  European Journal of Internal Medicine, 2024
• Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes
  Canadian Journal of Diabetes, 2021
• GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice
  Clinical Therapeutics, 2020
• Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
  Diabetes Research and Clinical Practice, 2019
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
  New England Journal of Medicine, 2016
• Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
  JACC: Heart Failure, 2016
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
  New England Journal of Medicine, 2015
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
  New England Journal of Medicine, 2015
• Insulin Therapy and Hypoglycemia
  Endocrinology and Metabolism Clinics of North America, 2012
• Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies
  Pharmaceutical Statistics, 2011